Frontiers in Bioengineering and Biotechnology (Jan 2024)

Genetically engineered CD80–pMHC-harboring extracellular vesicles for antigen-specific CD4+ T-cell engagement

  • Irina A. Ishina,
  • Inna N. Kurbatskaia,
  • Azad E. Mamedov,
  • Elena I. Shramova,
  • Sergey M. Deyev,
  • Sergey M. Deyev,
  • Sergey M. Deyev,
  • Kamila S. Nurbaeva,
  • Yury P. Rubtsov,
  • Yury P. Rubtsov,
  • Alexey A. Belogurov,
  • Alexey A. Belogurov,
  • Alexander G. Gabibov,
  • Alexander G. Gabibov,
  • Alexander G. Gabibov,
  • Maria Y. Zakharova,
  • Maria Y. Zakharova

DOI
https://doi.org/10.3389/fbioe.2023.1341685
Journal volume & issue
Vol. 11

Abstract

Read online

The identification of low-frequency antigen-specific CD4+ T cells is crucial for effective immunomonitoring across various diseases. However, this task still encounters experimental challenges necessitating the implementation of enrichment procedures. While existing antigen-specific expansion technologies predominantly concentrate on the enrichment of CD8+ T cells, advancements in methods targeting CD4+ T cells have been limited. In this study, we report a technique that harnesses antigen-presenting extracellular vesicles (EVs) for stimulation and expansion of antigen-specific CD4+ T cells. EVs are derived from a genetically modified HeLa cell line designed to emulate professional antigen-presenting cells (APCs) by expressing key costimulatory molecules CD80 and specific peptide–MHC-II complexes (pMHCs). Our results demonstrate the beneficial potent stimulatory capacity of EVs in activating both immortalized and isolated human CD4+ T cells from peripheral blood mononuclear cells (PBMCs). Our technique successfully expands low-frequency influenza-specific CD4+ T cells from healthy individuals. In summary, the elaborated methodology represents a streamlined and efficient approach for the detection and expansion of antigen-specific CD4+ T cells, presenting a valuable alternative to existing antigen-specific T-cell expansion protocols.

Keywords